A census of human cancer genes

Nature Reviews Cancer

Volumn 4, Issue 3, 2004, Pages 177-183

  Futreal, P Andrew ^a   Coin, Lachlan ^a   Marshall, Mhairi ^a   Down, Thomas ^a   Hubbard, Timothy ^a   Wooster, Richard ^a   Rahman, Nazneen ^b   Stratton, Michael R ^a,b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLT3 LIGAND; FRAGILE HISTIDINE TRIAD PROTEIN; G PROTEIN COUPLED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN RET; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR; TRANSCRIPTION FACTOR PAX8; TRANSFORMING GROWTH FACTOR BETA2; ZINC FINGER PROTEIN;

CANCER GENETICS; CANCER RESEARCH; CARCINOGENESIS; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN GENOME; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

EID: 1542515338     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1299     Document Type: Review

References (42)

1. Reddy, E. P., Reynolds, R. K., Santos, E. & Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300, 149-152 (1982).
2. Tabin, C. J. et al. Mechanism of activation of a human oncogene. Nature 300, 143-149 (1982). References 1 and 2 are seminal papers that defined the existence of oncogene sequences in cancer-cell genomes and that first identified a mutation involved in human cancer.
3. Parsons, R. et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75, 1227-1236 (1993).
4. Fishel, R. et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1027-1038 (1993).
5. Leach, F. S. et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75, 1215-1225 (1993).
6. Merlo, A. et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686-692 (1995).
7. Kane, M. F. et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808-811 (1997).
8. Baylin, S. & Bestor, T. H. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1, 299-305 (2002).
9. Duval, A. & Hamelin, R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 62, 2447-2454 (2002).
10. Duval, A. et al. Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. Hum. Mol. Genet. 10, 513-518 (2001).
11. Grady, W. M. et al. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res. 59, 320-324 (1999).
12. Ohta, M. et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84, 587-597 (1996).
13. Bednarek, A. K. et al. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 60, 2140-2145 (2000).
14. Sutherland, G. R., Baker, E. & Richards, R. I. Fragile sites still breaking. Trends Genet. 14, 501-506 (1998).
15. Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440 (1994).
16. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1946 (1997).
17. Laken, S. J. et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genet. 17, 79-83 (1997).
18. Meijers-Heijboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet. 31, 55-59 (2002).
19. Shih, C., Shilo, B. Z., Goldfarb, M. P., Dannenberg, A. & Weinberg, R. A. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc. Natl Acad. Sci. USA 76, 5714-5718 (1979).
20. Krontiris, T. G. & Cooper, G. M. Transforming activity of human tumor DNAs. Proc. Natl Acad. Sci. USA 78, 1181-1184 (1981).
21. Baker, S. J. et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50, 7717-7722 (1990).
22. Hwang, S.-J., Lozano, G., Amos, C. I. & Strong, L. C. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am. J. Hum. Genet. 72, 975-983 (2003).
23. Hemminki, A. et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184-187 (1998).
24. Sanchez-Cespedes, M. et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62, 3659-3662 (2002).
25. Futreal, P. A. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120-122 (1994).
26. Lancaster, J. M. et al. BRCA2 mutations in primary breast and ovarian cancers. Nature Genet. 13, 238-240 (1996).
27. Nikiforov, Y. E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 13, 3-16 (2002).
28. Kroll, T. G. et al. PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma. Science 289, 1357-1350 (2000).
29. Sidhar, S. K. et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum. Molec. Genet. 5, 1333-1338 (1996).
30. Tognon, C. et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2, 367-376 (2002).
31. Ayton, P. M. & Cleary, M. L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20, 5695-5707 (2001).
32. Eng, C. & Mulligan, L. M. Mutations of the RET protooncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum. Mutat. 9, 97-109 (1997).
33. Wong, A. J. et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl Acad. Sci. USA 89, 2965-2969 (1992).
34. Zhuang, Z. et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genet. 20, 66-69 (1998).
35. Bongarzone, I. et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RIα of cyclic AMP-dependent protein kinase A. Molec. Cell. Biol. 13, 358-366 (1993).
36. Kirschner, L. S. et al. Mutations of the gene encoding the protein kinase A type 1-α regulatory subunit in patients with the Carney complex. Nature Genet. 26, 89-92 (2000).
37. Bateman, A. et al. The Pfam protein families database. Nucleic Acids Res. 30, 276-280 (2002).
38. Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749-1753 (1995).
39. Howe, J. R. et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nature Genet. 28, 184-187 (2001).
40. Gilliland, D. G. & Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100, 1532-1542 (2002).
41. Hirota, S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580 (1998).
42. Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710 (2003).